

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**11 May 2024 :: Issue 750**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

**Request email delivery of the pdf:** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

**Support this knowledge-sharing service:** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

## ***Milestones, Perspectives***

.....  
.....

### **Pandemic Accord**

#### **Governments agree to continue their steady progress on proposed pandemic agreement ahead of the World Health Assembly**

10 May 2024 *News release*

Governments of the world today agreed to continue working on a proposed pandemic agreement, and to further refine the draft, ahead of the Seventy-seventh World Health Assembly that starts 27 May 2024.

Governments meeting at the World Health Organization headquarters in Geneva agreed to resume hybrid and in-person discussions over coming weeks to advance work on **critical issues, including around a proposed new global system for pathogen access and benefits sharing (i.e. life-saving vaccines, treatments and diagnostics); pandemic prevention and One Health; and the financial coordination needed to scale up countries' capacities to prepare for and respond to pandemics...**

INB Bureau Co-Chair Dr Precious Matsoso, from South Africa, said progress had been made during this latest round of discussions on a wide range of issues contained in the draft agreement...

.....

#### ***Editor's Note:***

Beyond the announcement above, we did not identify that the Intergovernmental Negotiating Body has provided any details on the status of negotiations on specific outstanding issues and there was no new draft posted, representing the work of the resumed session which ran from April 29 – May 10, 2024.

The posted information on this resumed session notes "The closing plenary session of the INB is open to WHO Member States, Associate Members, Observers and regional economic integration organizations, as well all relevant stakeholders. The session will be publicly webcast and archived for later viewing. Substantive negotiating sessions will be held in closed format." We did not identify any posted content that aligns with this notice.

.....  
.....

### **World Health Assembly – WHO Results Report 2023**

#### **WHO Results Report 2023 shows notable health achievements and calls for concerted drive toward Sustainable Development Goals**

7 May 2024 *News release*

*[Excerpts]*

The World Health Organization (WHO) Results Report 2023, the most comprehensive to date, showcases achievement of key public health milestones, even amid greater global humanitarian health needs driven by conflict, climate change and disease outbreaks.

The report is released ahead of the 2024 Seventy-seventh World Health Assembly, which runs 27 May – 1 June 2024. WHO's revised Programme Budget for 2022–2023 was US\$ 6726.1 million, incorporating lessons learned from the pandemic response and addressing emerging health priorities...

### ***Triple billion targets***

**"The world is off track to reach most of the triple billion targets and the health-related Sustainable Development Goals,"** said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "However, with concrete and concerted action to accelerate progress, we could still achieve a substantial subset of them. Our goal is to invest even more resources where they matter most—at the country level—while ensuring sustainable and flexible financing to support our mission."

**The report shows advancement in several key areas, including healthier populations, universal health coverage (UHC), and health emergencies protection.**

Related to healthier populations, the current trajectory indicates the target of 1 billion more people enjoying better health and well-being will likely be met by 2025, driven primarily by improvements in air quality and access to water, sanitation and hygiene measures.

In terms of UHC, 30% of countries are moving ahead in coverage of essential health services and providing financial protection. This is largely due to increased HIV service coverage.

**Regarding emergencies protection, though the coverage of vaccinations for high-priority pathogens shows improvement relative to the COVID-19 pandemic-related disruptions in 2020–2021, it has not yet returned to pre-pandemic levels.**

**The Pandemic Fund's first disbursements totaled US\$ 338 million in 2023, supporting 37 countries with financing to strengthen prevention, preparedness and response capacities.\*** WHO continues to work with countries and partners to enhance genomic sequencing capabilities and strengthen laboratory and surveillance systems worldwide with capacity increased by 62% for SARS-CoV-2 between February 2021 and December 2023.

### ***Prominent points***

**The world's first malaria vaccine, RTS,S/AS01, was administered to more than two million children in Ghana, Kenya, and Malawi** during the biennium, reducing mortality by 13% among children eligible for vaccination. **WHO's prequalification of a second vaccine, R21/Matrix-M, is expected to further boost malaria control efforts.**

Elsewhere, 14 countries eliminated at least one neglected tropical disease from 2022–2023. Bangladesh eliminated 2.

**The first-ever all-oral treatment regimens for multidrug-resistant tuberculosis were made available in 2022,** allowing the highest number of people with tuberculosis to get treatment since monitoring began almost 30 years ago.

Thanks to WHO's REPLACE initiative, which aims to eliminate industrially-produced trans-fatty acids from the food supply, an additional 13 countries implemented best-practice policies, bringing the total to 53 countries.

**More than 75% of people living with HIV are receiving antiretroviral therapy, with most achieving viral suppression** -- meaning they cannot infect others. WHO's guidance and support have helped countries like Botswana achieve significant progress in controlling HIV transmission.

Tobacco use is declining in 150 countries, 56 of which are on track to achieve the global target for reducing tobacco use by 2025.

An additional 29 countries developed multisectoral national action plans on antimicrobial resistance during the biennium 2022–2023, bringing the total to 178 countries.

Following the Director-General's call to **eliminate cervical cancer, another 25 countries have introduced the human papillomavirus vaccine, bringing the total to 58** that have introduced the vaccine since WHO launched the initiative in 2020.

### *The way forward*

**The report acknowledges significant disparities in health outcomes, disruptions caused by the COVID-19 pandemic, and that persistent health workforce shortages require investments in education and employment.**

Looking ahead, WHO's Programme Budget for 2024–2025 aims to balance investment in the Organization's normative functions with the need to strengthen country offices. It aims to fund 80% of the planned budget of high-priority items, thereby accelerating progress towards meeting the triple billion targets of the GPW 13 (current WHO strategy for the period 2019-2023).

.....  
.....

### **Featured Journal Content**

#### **Science Translational Medicine**

Volume 16| Issue 745| 1 May 2024

<https://www.science.org/toc/stm/current>

*Viewpoints*

#### **Vaccination for healthy aging**

BY David E. Bloom, Simone Pecetta, Francesco Berlanda Scorza, Andrea Carfi, Bruce Carleton, Mariateresa Cipriano [...] Rino Rappuoli

01 May 2024

*As the world's population grows older, vaccination is becoming a key strategy for promoting healthy aging. Despite scientific progress in adult vaccine development, obstacles such as immunosenescence and vaccine hesitancy remain. To unlock the potential of adult vaccines fully, we must enhance immunization programs, dispel misinformation, and invest in research that deepens our understanding of aging and immunity.*

*[Excerpt from opening text]*

...Here, we set forth a strategy for harnessing the full potential contribution of vaccination to healthy aging. **The strategy has three key, at times overlapping, components:**

- actions that take better advantage of existing knowledge and technologies,
- actions that expand our knowledge base and allow for timely development of new vaccines, and
- actions for efficient and widespread uptake of both existing (e.g., pneumococcal and flu) and new vaccines...

*[Excerpt from Conclusion]*

...Realizing the full potential benefits of adult vaccines will require a renewed commitment to vaccine development, implementation, and safety monitoring in this age group. **Proper vaccine investment requires a long-term vision in which funds are used today to support a long-term stream of future benefits**, making evaluation and acceptance by governments challenging. The COVID-19 pandemic taught a powerful lesson about the high societal and economic value of vaccination. We need to build on this learning to achieve the vision proposed here.

**In conclusion, we envision a golden age in the development of adult vaccines, which will appreciably improve the health, as well as the social and economic well-being, of aging populations.**

.....  
.....

## **Europe: One Health Framework**

### **[One Health: a joint framework for action published by five EU agencies](#)**

7 May 2024

Today, the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA), the European Environment Agency (EEA), the European Food Safety Authority (EFSA), and the European Medicines Agency (EMA) published a joint framework for action to strengthen cooperation to support the implementation of the One Health agenda in the European Union (EU).

One Health recognises the complex interplay between human, animal and plant health, food safety, the climate crisis and environmental sustainability. Implementing this approach across different sectors will be key to making the EU and its Member States better equipped to prevent, predict, detect and respond to health threats. It will mitigate the impact and societal cost of such threats, or even prevent their emergence, while also helping to reduce human pressures on the environment and safeguarding key societal needs such as food security and access to clean air and water.

A cross-agency task force will work on implementing the **joint framework for action** over the next three years (2024-2026), focusing on five strategic objectives: strategic coordination, research coordination, capacity building, stakeholder engagement and joint inter-agency activities. This will ensure that the scientific advice provided by the agencies is increasingly integrated, that the evidence base for One Health is strengthened and that the agencies are able to contribute with a common voice to the One Health agenda in the EU.

In November 2023, the five EU agencies that provide scientific advice on the environment, public health and food safety topics issued a joint statement expressing their shared commitment to supporting the One Health agenda in Europe.

On the occasion of the launch of the joint framework for action, the Executive Directors of the five EU Agencies reinforced their commitment to the One Health approach in a joint video statement

.....

### **[Cross-agency One Health task force framework for action](#)**

*Scientific and technical publications*

7 May 2024

Following the joint statement from the Executive Directors of the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA), the European Environment Agency (EEA), the European Food Safety Authority (EFSA) and the European Medicines Agency (EMA) on how to deliver 'Cross-agency knowledge for One Health Action', the Cross-agency One Health task force has prepared this framework for action. The document outlines the common vision and objectives of the task force and lists a set of concrete actions to achieve them.

### *Executive summary*

The vision of the task force is to enable EU agencies to successfully contribute to the implementation of the One Health approach in Europe, thereby making the EU and its Member States better able to prevent and respond to health threats. In order to achieve this vision, the task force aims to work towards **a more permanent and established form of transdisciplinary cooperation** between the EU agencies, upholding the four principles of coordination, collaboration, communication and capacity building.

### **The task force has identified the following five strategic objectives to guide its work:**

- Facilitate strategic coordination in the implementation of the One Health approach
- Promote research coordination and One Health-driven agenda setting
- Enhance capacity building on One Health
- Strengthen One Health communication and stakeholders' engagement
- Support the development of partnerships through joint One Health activities

**Figure 1:** Strategic objectives of the cross-agency One Health task force framework for action



Through these strategic objectives, the task force will help to strengthen the scientific evidence base for One Health, ensure that scientific advice and risk assessment are increasingly integrated, support the establishment of intersectoral coordination mechanisms, and build One Health capacities and skills.

**The actions will be implemented over a period of three years (2024-2026).** It is considered a living document and will be subject to adjustments to reflect progress and take on new challenges and initiatives.

:: [Cross-agency One Health task force framework for action](#) - EN - [PDF-790.65 KB]

.....  
.....

## **U.S. Biotechnology Regulation**

### **[EPA, FDA, and USDA Issue Joint Regulatory Plan for Biotechnology](#)**

May 08, 2024

... the **U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA)** have [developed a plan](#) to update, streamline, and clarify their regulations and oversight mechanisms for products of biotechnology...

The plan incorporates processes and timelines to **implement regulatory reform**, such as identifying guidance and regulations to update, streamline, or clarify, and identifying the potential need for new guidance or regulations. **The plan supports a whole-of-government approach to the regulation of biotechnology products.**

**The agencies have identified five major areas of biotechnology product regulation** where these actions will focus:

1. Modified plants
2. Modified animals
3. Modified microorganisms
4. Human drugs, biologics, and medical devices
5. Cross-cutting issues

#### **EPA, the FDA and USDA intend to implement the following joint efforts:**

- clarify and streamline regulatory oversight for genetically engineered (GE) plants, animals and microorganisms;
- update and expand their information sharing through an MOU to improve and broaden communication and coordination of oversight of modified microbes; and
- undertake a pilot project focused on modified microbes to explore and consider the feasibility and costs of developing a web-based tool that informs developers about which agency may regulate a given product category.

... the three regulatory Agencies, in consultation with the Office of Science and Technology Policy (OSTP), issued a **Request for Information (RFI) to the public to solicit information on regulatory ambiguities, gaps, uncertainties, or inefficiencies in the Coordinated Framework. The agencies received 88 distinct public comments, including a sign-on letter from over 6,000 members from biotechnology developers, producers, manufacturers, non-governmental organizations, and academia.** The Agencies will continue to engage with all interested stakeholders as they implement the plan.

Visit the [Unified Website for Biotechnology Regulation](#) for additional information on modernizing the regulatory system for biotechnology products and Executive Order 14081:



Enter Search Term(s):

 

## Resources



### | [VIEW FREQUENTLY ASKED QUESTIONS](#) |

[Coordinated Framework Documents](#)

[Informational Resources](#)

[Laws, Regulations, and Guidance](#)



## Polio – PHEIC

### [Polio this week as of 08 May 2024 - GPEI](#)

#### *Headlines*

:: The GPEI is seeking experts to serve in the Advisory Group on Sabin-IPV and Polio VLP Vaccine Development. Here are the [terms of reference](#).

:: On 4 May, Rotary International presented its Polio Eradication Champion Award to French President Emmanuel Macron in recognition of France's significant role in the global effort to eradicate polio. The ceremony was a feature of the Rotary Day event at UNESCO, centered on education and peace. [Read more...](#)

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Pakistan: 11 WPV1-positive environmental samples
- Angola: one cVDPV2 case
- Chad: one cVDPV2 case
- Guinea: seven cVDPV2-positive environmental samples
- Mozambique: one cVDPV2-positive environmental sample



#### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)



[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

**WHO & Regional Offices** [to 11 May 2024]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

10 May 2024 *News release*

[\*\*Governments agree to continue their steady progress on proposed pandemic agreement ahead of the World Health Assembly\*\*](#)

9 May 2024 *News release*

[\*\*New guidance aims to reduce bloodstream infections from catheter use\*\*](#)

7 May 2024 *News release*

[\*\*WHO Results Report 2023 shows notable health achievements and calls for concerted drive toward Sustainable Development Goals\*\*](#)

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region**

:: 06 May 2024

[\*\*African region's first-ever health workforce investment charter launched\*\*](#)

**WHO Region of the Americas PAHO**

:: 10 May 2024

[\*\*PAHO urges countries in the Southern Hemisphere to prepare for possible increase in respiratory diseases and dengue\*\*](#)

Washington, D.C., May 10, 2024 (PAHO) - The Pan American Health Organization (PAHO) has issued an epidemiological alert urging countries in the Southern Hemisphere to prepare for a possible simultaneous increase in influenza and other respiratory viruses, and dengue. With the onset of flu season and the persistent circulation of dengue in...

:: 10 May 2024

[\*\*Caribbean Mosquito Awareness Week 2024: PAHO calls to unite against dengue\*\*](#)

Washington, D.C., May 10, 2024 (PAHO)- The Pan American Health Organization (PAHO) is calling countries and territories of the Caribbean to join forces during Caribbean Mosquito Awareness Week 2024, which runs from May 6 to 12. The aim of the week is to kick start regional efforts to prevent and control dengue, chikungunya, and...

:: 7 May 2024

[\*\*Belize, Jamaica and St. Vincent and the Grenadines eliminate mother-to-child transmission of HIV and Syphilis\*\*](#)

Kingston, Jamaica, 7 May 2024 – Belize, Jamaica, and St. Vincent and the Grenadines are the latest countries in the Americas to receive certification from the World Health Organization (WHO) for eliminating the mother-to-child transmission of HIV and syphilis (EMTCT). The milestone was marked today at a commemorative event organized by the...

## **WHO South-East Asia Region SEARO**

*No new digest content identified.*

## **WHO European Region EURO**

*No new digest content identified.*

## **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified.*

## **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

### **[8 May 2024 | Hepatitis E - Chad](#)**

### **[8 May 2024 | Middle East respiratory syndrome coronavirus-Kingdom of Saudi Arabia](#)**

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 19, pp. 225–248 10 May 2024**

<https://iris.who.int/bitstream/handle/10665/376738/WER9919-eng-fre.pdf>

:: Malaria vaccines: WHO position paper

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

10 May 2024

### **[A global mandate to strengthen emergency, critical and operative care](#)**

8 May 2024

### **[Strengthening pandemic preparedness and response through integrated modelling](#)**

*Overview*

The far-reaching impacts of the COVID-19 pandemic underscore the critical need for evidence-informed, transparent and inclusive decision-making. Policy-makers have grappled with complex choices amidst uncertainty. With the increasing threat of emerging pandemic-prone pathogens, new

guidance released jointly by the World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD) and the World Bank elucidates the role of mathematical modelling – specifically integrated modelling – in addressing these challenges.

8 May 2024

[\*\*Digital adaptation kit for tuberculosis: operational requirements for implementing WHO recommendations...\*\*](#)

6 May 2024

[\*\*A survey of users on the WHO insecticide susceptibility tube test kit\*\*](#)

6 May 2024

[\*\*A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals – The Nigeria Context\*\*](#)

6 May 2024

[\*\*A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals – The Bangladesh context\*\*](#)

6 May 2024

[\*\*A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals – The Tunisia context\*\*](#)

6 May 2024

[\*\*A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals – The Kenya context\*\*](#)

6 May 2024

[\*\*A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals – The Pakistan context\*\*](#)

5 May 2024

[\*\*Global report on neglected tropical diseases 2024\*\*](#)

*Overview*

This document is the second in a series of global reports describing progress towards the 2030 targets set in Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. It describes a wide range of activities, accomplishments and challenges across the portfolio of NTDs and across all six WHO regions.

The report presents epidemiological and programmatic data for 2022, which were gathered, compiled and analysed in 2023. In some cases, 2023 data are available and presented; in other cases, less recent information is included, when 2022 data are not available. In addition, it presents the main facts or events that occurred in 2023.

3 May 2024

[\*\*WHO competency framework, risk communication and community engagement\*\*](#)

*Overview*

The risk communication and community engagement (RCCE) competency framework is a resource that details the essential behaviours and activities necessary for effective communication and engagement with communities before, during and after public health emergencies. The purpose of this framework is to establish and promote a common understanding of behavioural competencies and how they should

be applied for high-performing and community-centred health emergency programmes. It is intended to support the development of standardized training programmes, professional development and talent acquisition and to enhance the capabilities of public health professionals involved in RCCE. Its goal is to inform the establishment of a skilled, well-trained RCCE workforce that consistently understands and executes the necessary behaviours and activities required to conduct RCCE activities with competence and professionalism.

.....  
.....

## **USA – HHS, FDA, CDC**

### **HHS**

*News*

#### **[Fact Sheet: USDA, HHS Announce New Actions to Reduce Impact and Spread of H5N1](#)**

May 10, 2024 News Release

#### **[COVID-19 Vaccination Public Education Campaign Saved Thousands of Lives, Billions of Dollars](#)**

May 6, 2024 *News Release*

The U.S. Department of Health and Human Services' (HHS) COVID-19 Vaccination Public Education Campaign, We Can Do This, resulted in an estimated \$731.9 billion in societal benefits due to averted illness and related costs, resulting in a nearly \$90 return in societal benefits for every \$1 spent, according to research published today in the *American Journal of Preventive Medicine*...

### **FDA**

*Press Announcements*

#### **[May 8, 2024 - EPA, FDA, and USDA Issue Joint Regulatory Plan for Biotechnology](#)**

### **FDA VRBPAC**

*Advisory Committee Calendar*

#### **[Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024](#)**

**CDC/ACIP [U.S.]** [to 11 May 2024]

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

#### **[Readout of CDC Call with State Public Health Partners Regarding Avian Influenza and Farmworker Protection](#)**

May 6, 2024

### **ACIP Meetings**

*Next ACIP Meeting*

June 26-28

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

**May 9, 2024 / No. 18**

[PDF of this issue](#)

- [Shiga Toxin–Producing Escherichia coli O157:H7 Illness Outbreak Associated with Untreated, Pressurized, Municipal Irrigation Water — Utah, 2023](#)
- [Notes from the Field: Increases in Imported Malaria Cases — Three Southern U.S. Border Jurisdictions, 2023](#)
- [Notes from the Field: Potential Outbreak of Extrapulmonary Mycobacterium abscessus subspecies massiliense Infections from Stem Cell Treatment Clinics in Mexico — Arizona and Colorado, 2022](#)

.....  
 .....

## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### [Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 22-25 April 2024](#)

EMA's human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.

7 May 2024

#### [One Health: a joint framework for action published by five EU agencies](#)

Today, the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA), the European Environment Agency (EEA), the European Food Safety Authority (EFSA), and the European Medicines Agency (EMA) published a joint framework for action to strengthen cooperation to support the implementation of the One Health agenda...

7 May 2024

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*News*

#### [Increase in pertussis cases in EU/EEA: infants under six months of age at the highest risk](#)

8 May 2024

#### [One Health: a joint framework for action published by five EU agencies](#)

7 May 2024

*Surveillance report*

#### [Influenza virus characterization - Summary Europe, March 2024](#)

8 May 2024

This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 August 2023 until 31 January 2024.

*Assessment*

#### [Increase of pertussis cases in the EU/EEA](#)

8 May 2024

Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.

.....  
.....

**Africa CDC** [to 11 May 2024]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

*No new digest content identified.*

.....  
.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 11 May 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 11 May 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC**

**Weekly Reports: Current Volume (6)**

**2024-05-10 / No. 19 VACCINE ISSUE**

[View PDF of this issue](#)

- [Preplanned Studies: Estimated Human Papillomavirus Vaccine Coverage Among Females 9–45 Years of Age — China, 2017–2022](#)
- [Preplanned Studies: Coverage of the Combined DTaP-IPV/Hib Vaccine Among Children Aged 2–18 Months — 9 PLADs, China, 2019–2021](#)
- [Preplanned Studies: Comparison of 1 Versus 2 Doses of Quadrivalent Influenza Vaccine in 3–8-Year-Old Children with Different Immunological States — Jiangsu Province, China, 2021](#)
- [Preplanned Studies: Occurrence and Reduction of Hepatitis B Vaccine Hesitancy Among Medical University Students — Shanxi Province, China, 2020](#)
- 

.....  
.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 11 May 2024]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 11 May 2024]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*Press release* May 06, 2024

### **[Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact](#)**

*Joint partnership will support science to tackle a series of global health challenges and build healthier futures, especially for the world's most vulnerable populations*

HELSINGØR, DENMARK (May 6, 2024) – The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US\$100 million, for a total of US\$300 million. Initial funding will support solutions to address the health impacts of climate change; infectious disease and antimicrobial resistance (AMR); and greater understanding of the interplay between nutrition, immunity, disease, and developmental outcomes...

**Bill & Melinda Gates Medical Research Institute** [to 11 May 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 11 May 2024]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 11 May 2024]

<http://cepi.net/>

*Latest News*

*No new digest content identified.*



**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 11 May 2024]

<https://cioms.ch/>

*News; Publications; Events*

**[PUBLIC CONSULTATION OF THE DRAFT SCAR \[Severe Cutaneous Adverse Reactions\] REPORT IS NOW OPEN!](#)**

**Deadline: Friday 7 June 2024**

*Working Group objectives*

To establish a balanced, efficient, global perspective on SCAR detection, susceptibility factors, severity, outcome and probability through causality assessment tools, monitoring and management during the drug development and post-marketing phases.

:: [Draft report](#)

:: [Comment form](#)

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 11 May 2024]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 11 May 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 11 May 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [to 11 May 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 11 May 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 11 May 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

**[Prevalence of tuberculosis, hepatitis B, and HIV among asylum seekers and refugees in the UK](#)**

Added May 10, 2024

**[Vaccine hesitancy](#)**

Added May 5, 2024

**Fondation Merieux** [to 11 May 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 11 May 2024]

<https://www.gavi.org/>

*Press Releases*

10 May 2024

**[Gavi and Government of Lesotho announce resumption of direct funding](#)**

**GE2P2 Global Foundation** [to 11 May 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 17 April 2024 – Issue 16](#)

**GHIT Fund** [to 11 May 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 11 May 2024]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

06 May 2024

**[Global Fund Hails Launch of Africa Health Workforce Investment Charter](#)**

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), warmly welcomes the launch of the Africa Health Workforce Investment Charter, which was signed today in Windhoek, Namibia, at the Africa Health Workforce Investment Forum.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 11 May 2024]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 11 May 2024]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 11 May 2024]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 11 May 2024]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 11 May 2024]

<https://www.iavi.org/>

*News, Features*

*Features*

[IAVI's Human Immunology Laboratory relocates samples to Africa, fulfilling capacity strengthening goal](#)

May 7, 2024

**INSERM** [to 11 May 2024]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 11 May 2024]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 11 May 2024]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

**[African Union, ICRC Roundtable Seeks Innovative Tech Solutions for Landmine Clearance in Africa](#)**

The roundtable brought together representatives from 8 high-risk African Member States alongside countries with successful demining programs. Operational demining actors such as UNMAS also participated.

09-05-2024 | Article

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 11 May 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

**[World Red Cross and Red Crescent Day: 8 May is a chance to celebrate and commemorate](#)**

07/05/2024 | *Press release*

**Institut Pasteur** [to 11 May 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 11 May 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*News*

**[International Science Council Governing Board calls for science and scientists in Africa to be mobilized ahead of 2024 United Nations Summit of the Future](#)**

The clear message coming from the International Science Council Governing Board, is that science continues to be underutilized as a pathway to achieve the Sustainable Development Goals.

09.05.2024

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 11 May 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 11 May 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

**[International Vaccine Institute, Baylor College of Medicine, and Regional Center for Innovation in Vaccines and Biopharmaceuticals AIP exchange an MOU to advance global health research and capability](#)**

May 8, 2024

...With the signing of a memorandum of understanding (MOU), the three organizations aim to strengthen capabilities in the vaccine sciences and the biopharmaceutical research & development industry in Panama and the greater Latin America region...

**Johns Hopkins Center for Health Security** [to 11 May 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 11 May 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Gaza-Israel war*

**[Thousands forced to flee as Israeli military offensive intensifies and aid is blocked in Rafah](#)**

Press Release 8 May 2024

**National Academy of Medicine** - USA [to 11 May 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 11 May 2024]

<https://www.nationalacademies.org/newsroom?>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 11 May 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

June 13-14, 2024

**NIH** [to 11 May 2024]

<http://www.nih.gov/>

*New Releases*

Wednesday, May 8, 2024

**[NIH to open long COVID clinical trials to study sleep disturbances, exercise intolerance, and post exertional malaise](#)**

Part of the NIH RECOVER Initiative, trials will test four treatments.

**Sabin Vaccine Institute** [to 11 May 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 11 May 2024]

<http://www.unaids.org/en>

*News, Stories, Updates*

*No new digest content identified.*

**UNICEF** [to 11 May 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

*Remarks* 10 May 2024

**[As Rafah needs rise, humanitarian response forced to 'scrape the bottom of the barrel'](#)**

GENEVA/RAFAH, Gaza, 10 May 2024 – “Thank you, and greetings from Rafah in Gaza. I have been working on large-scale humanitarian emergencies for the best part of the last 30 years and I've never been involved in a situation as devastating, complex or erratic as this. “When I arrived in Gaza in the middle of November, I was shocked by the severity...

*Statement* 09 May 2024

**[Statement by UNICEF Executive Director Catherine Russell on military operations and border closures in Rafah, Gaza](#)**

NEW YORK, 9 May 2024 – “The humanitarian response of UNICEF and our partners — and thus the lives of all the children and their families in the Gaza Strip who depend on it — requires fuel. We need fuel to move lifesaving supplies – medicine, treatments for malnutrition, tents and water pipes – as well as staff to reach children and families in...

*Press release* 07 May 2024

**[Belize, Jamaica and St. Vincent and the Grenadines eliminate mother-to-child transmission of HIV and syphilis](#)**

Kingston, Jamaica, 7 May 2024 – Belize, Jamaica, and St. Vincent and the Grenadines are the latest countries in the Americas to receive certification from the World Health Organization (WHO) for eliminating the mother-to-child transmission of HIV and syphilis (EMTCT). The milestone was marked today at a commemorative event organized by the Pan...

**Unitaid** [to 11 May 2024]

<https://unitaid.org/>

*Featured News*

06 May 2024

**[Industry Engagement Forum in Lagos aims to increase health product manufacturing in Africa](#)**

The 2024 Industry Engagement Forum, themed “Unlocking Healthcare Value Chains and Driving Investment through Partnerships: Accelerating Equitable Access to Quality-Assured Sustainable Health Products,” is set to take place from May 7-9, 2024, in Lagos, Nigeria. More than 300 participants are scheduled to attend the forum, which aims to accelerate equitable access to urgently needed health products through collaborative partnerships, and to facilitate investment opportunities as interventions to expand local pharmaceutical manufacturing.

The forum is co-convened by the African Development Bank (AfDB), the International Finance Corporation (IFC), and the global health organization Unitaid in association with Nigeria’s Presidential Initiative on Unlocking Healthcare Value Chains (PVAC). The initiative reflects a strategic move to unlock billions in new investments and reshape Nigeria’s and Africa’s health care landscape through multifaceted partnerships and substantial financial commitments.

While Africa shoulders 25% of the world’s disease burden – including major infectious diseases like HIV, tuberculosis, and malaria – more than 95% of the active pharmaceutical ingredients and 70% of the pharmaceuticals consumed on the continent are imported. This leaves countries vulnerable to price volatility, supply chain disruptions, or unavailability of essential health products, particularly during periods of supply scarcity in the face of surges in regional or global demand or after climate-related shocks or extreme weather events...

**Vaccine Equity Cooperative [nee Initiative]** [to 11 May 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 11 May 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 11 May 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 11 May 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*



**Wellcome Trust** [to 11 May 2024]

<https://wellcome.org/>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 11 May 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Bank** [to 11 May 2024]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 11 May 2024]

<https://www.wfpha.org/>

*Event*

*No new digest content identified.*

**World Medical Association [WMA]** [to 11 May 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health** [to 11 May 2024]

<https://www.oie.int/en/>

*Press Releases, Statements*

Statements

**[High Pathogenicity Avian Influenza in Cattle](#)**

Published on 5 April 2024

*Updated on 8 May 2024*

The ongoing spread of High Pathogenicity Avian Influenza (HPAI) in different regions of the world, alongside the recent detections of cases in cattle, is raising concerns within the international community.

While HPAI primarily affects poultry and wild birds, avian influenza can occasionally be transmitted to mammals, including humans. In the last two years, an increasing number of H5N1 avian influenza cases are being reported in terrestrial and aquatic mammalian animals.

The recently reported detections of HPAI in dairy cattle in the United States of America, have raised international concerns. Infected cattle may be asymptomatic or with mild illness showing non-specific clinical signs such as decreased milk production, thicker-colostrum-like milk, reduced appetite, lethargy, fever and dehydration. These infections in cattle could indicate an increased risk of H5N1 viruses becoming better adapted to mammals, and potentially spilling over to humans and other livestock...

*WOAH calls on its Members to:*

- :: Maintain enhanced avian influenza SURVEILLANCE in domestic and wild birds.
- :: INCLUDE HPAI as a differential diagnosis, in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses, in particular:
  - . Animals showing clinical signs compatible with avian influenza;
  - . Sick or dead domestic animals near affected premises;
  - . Suspected, including apparently healthy animals, that have been exposed to or epidemiologically linked to suspected or confirmed HPAI in birds or cattle (i.e. situated in HPAI high-risk areas or in areas where avian influenza has been confirmed).
- :: REPORT cases of HPAI in all animal species, including unusual hosts, to WOAHP through its World Animal Health Information System (WAHIS)
  - . Genetic sequences of avian influenza viruses should be shared in publicly available databases.
- :: CONSIDER poultry vaccination as complementary avian influenza control measure;
- :: PREVENT the introduction and spread of the disease by implementing strict biosecurity measures in livestock holdings, in particular in milking parlour and
- :: EMPLOY good production and hygiene practices
  - \_ when handling animal products. Raw milk or raw milk products from HPAI infected cows or exposed to those infected with HPAI should not be used to feed animals or for human consumption.
- :: PROTECT humans in close contact with or handling sick cattle or other sick livestock and their products. Exposed humans should always take precautionary measures to avoid getting infected and minimize the risk to mechanically carry the virus that could infect livestock or companion animals. This should include wearing personal protective equipment, avoiding visiting other livestock premises after the exposure and implementing standard food safety measures when handling animal products from exposed livestock.
- :: AVOID implementing unjustified trade restrictions. Import risk management measures should be scientifically justified and in line with the WOAHP International Standards.

.....  
 .....

**ARM [Alliance for Regenerative Medicine]** [to 11 May 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 11 May 2024]

<https://www.bio.org/press-releases>

*Press Releases*

**[BIO Statement on EPA/FDA/USDA Release of Plans for Reforming Regulation of Animal, Microbial and Plant Biotechnology](#)**

May 8, 2024

"BIO is pleased to see today's report released by EPA, FDA and USDA outlining the joint plan for regulatory reform under the Coordinated Framework for Regulation of Biotechnology to support and sustain biotech innovation and continue growing the U.S. bioeconomy..."

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 11 May 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 11 May 2024]

<https://internationalbiotech.org/news/>

*News*

*Website not responding at inquiry.*

**IFPMA** [to 11 May 2024]

<https://ifpma.org/>

*News*

*No new digest announcements identified.*

**International Alliance of Patients' Organizations – IAPO** [to 11 May 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 11 May 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

**AstraZeneca**

*Press Releases*

**BBC - [AstraZeneca to withdraw Covid vaccine](#)**

By James Gallagher, Health and science correspondent

After more than three billion doses, the Oxford-AstraZeneca Covid vaccine is being withdrawn. AstraZeneca said it was "incredibly proud" of the vaccine, but it had made a commercial decision.

It said the rise of new coronavirus variants meant demand had shifted to the newer updated vaccines...

**Bharat Biotech**

*Press Releases* - *No new digest announcements identified.*

**BioCubaFarma** – Cuba

Últimas Noticias - No new digest announcements identified

## **Biological E**

News - No new digest announcements identified

## **BioNTech**

Press Releases - No new digest announcements identified.

## **Boehringer**

Press Releases

### **Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials**

Joint collaborations bring Boehringer Ingelheim's Phase III clinical trial to communities through Walgreens pharmacy clinical trial centers and EmVenio's mobile research units, aimed at improving access to trials

May 2, 2024

## **CanSinoBIO**

News - Website not responding at inquiry

## **CIGB**

Latest News - No new digest announcements identified.

## **Cinnagen**

Recent News - No new digest announcements identified.

## **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

## **Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media - No new digest announcements identified.

## **EuBiologics, S Korea**

News - No new digest announcements identified.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **Janssen/JNJ**

Press Releases - No new digest announcements identified.

## **Merck**

News releases

May 08, 2024

## [Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers](#)

### **Moderna**

#### *Press Releases*

#### [Moderna Announces Update on Investigational RSV Vaccine](#)

CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna's investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.

The FDA has not informed Moderna of any issues related to vaccine safety, efficacy or quality that would prevent the approval of mRNA-1345.

Moderna remains on track for mRNA-1345 to be reviewed at the CDC's Advisory Committee on Immunization Practices (ACIP) June 26-27, 2024, meeting, which is necessary prior to commercial launch.

"Moderna is very grateful to the FDA for their continued efforts and diligence," said Stephen Hoge, M.D., President of Moderna. "We look forward to helping the agency complete the review of our application, and to the June ACIP meeting."...

### **Nanogen**

*News - No new digest announcements identified*

### **Novartis**

*News - No new digest announcements identified.*

### **Novavax**

#### *Press Releases*

May 10, 2024

#### [Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines](#)

- Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
- Provides Novavax with cash and an equity investment totalling approximately \$1.2 billion (upfront payment of \$500 million and up to \$700 million in additional development, regulatory and launch milestones), plus tiered royalties
- Novavax is entitled to additional launch and sales milestone opportunities of up to \$200 million, plus mid-single digit royalties, for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M™ adjuvant technology
- Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection

### **Pfizer**

#### *Recent Press Releases*

#### [Pfizer Announces New Chief Strategy and Innovation Officer](#)

Monday, May 06, 2024 -

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will

be a member of Pfizer's Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research...

### **R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

### **Sanofi Pasteur**

*Press Releases*

May 10, 2024

[\*\*Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines\*\*](#)

### **Serum Institute of India**

*NEWS & ANNOUNCEMENTS - No new digest announcements identified*

### **Sinopharm/WIBPBIBP**

*News - No new digest announcements identified*

### **Sinovac**

*Press Releases - No new digest announcements identified*

### **SK Biosciences**

*Press Releases - No new digest announcements identified.*

### **Takeda**

*Newsroom - No new digest announcements identified.*

### **Valneva**

*Press Releases*

[\*\*Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates\*\*](#)

May 7, 2024

*...Strong R&D execution*

- Single-shot chikungunya vaccine IXCHIQ® recommended by ACIP and adopted by U.S. CDC[3]; Regulatory processes with the European, Canadian and Brazilian authorities on track;
- Six-month data for Phase 3 adolescent study of IXCHIQ® to be reported shortly and label extensions to be submitted based on results; Enrolment of children for pediatric Phase 2 study on track;
- Primary vaccinations for all participants in the VALOR Lyme disease Phase 3 trial expected to be completed in Q2;
- Phase 1 clinical trial for second-generation Zika vaccine candidate initiated[4].

### **Vector State Research Centre of Virology and Biotechnology**

*Home - Website not responding [404 error]*

### **WestVac Biopharma**

*Media - No new digest announcements identified.*

### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
Website [No News/Announcements page identified]

.....  
.....

**Contents** [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)

.....  
.....

**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

**AJOB Empirical Bioethics**

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

**AMA Journal of Ethics**

Volume 26, Number 5: E361-433 May 2024

<https://journalofethics.ama-assn.org/issue/antimicrobial-resistance>

**Antimicrobial Resistance**

Microbes include bacteria, parasites, viruses, and fungi that constantly evolve. Antimicrobial resistance (AMR) happens when microbes change, becoming harder to treat in individual human and nonhuman animals and plants with antibiotic, antiparasitic, antiviral, and antifungal agents. Resistant pathogens are easily transmissible across human and nonhuman ecology, and this theme issue attends to ethical, clinical, and policy dimensions of this set of problems. National and international burden of AMR has been assessed in terms of infection incidence, deaths, hospital length of stay, and location-specific costs of developing and applying specific pathogen-drug combinations to try to save lives and preserve food supplies. Routine and focused surveillance is key to understanding microbiological, individual, social, and ecological root causes, downstream effects, and sources of domestic and global inequity in AMR.

**American Journal of Human Genetics**

May 02, 2024 Volume 111 Issue 5 p807-996



<https://www.cell.com/ajhg/current>

[Reviewed earlier]

**American Journal of Infection Control**

May 2024 Volume 52 Issue 5 p501-624

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

May 2024 Volume 66 Issue 5 p751-926

<https://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

May 2024 114(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 110 (2024): Issue 5 (May 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/4/tpmd.110.issue-5.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

April 2024 Volume 177, Issue 4

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 330 May 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/330/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 11 May 2024)

[No new digest content identified]

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 11 May 2024)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 11 May 2024)

[No new digest content identified]

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 11 May 2024)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 11 May 2024)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 11 May 2024)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 11 May 2024)

[\*\*SARS-CoV-2 vaccine breakthrough infection and the evaluation of safety precaution practice before and after vaccination among healthcare workers in South West, Nigeria\*\*](#)

*Worldwide, it has been reported that fully vaccinated people still die of COVID-19-associated symptoms, generating public uncertainty about the safety and effectiveness of the vaccines. Hence, this research is...*

Authors: Oluwatosin Idowu Oni, Patrick Olanrewaju Osho, Tayelolu Mary Odesanmi, Habeebat Motunrayo Raji, Faith Titilayo Oluranti and Demian Ibina

Citation: BMC Public Health 2024 24:1259

Content type: Research Published on: 8 May 2024

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 11 May 2024)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

April 2024 - Volume 29 - 2

<https://ebm.bmj.com/content/29/2>

[Reviewed earlier]

**BMJ Global Health**

April 2024 - Volume 9 - Suppl 1

[https://gh.bmj.com/content/9/Suppl\\_1](https://gh.bmj.com/content/9/Suppl_1)

***Social determinants of health equity***

[Reviewed earlier]

**Bulletin of the Atomic Scientists**

March 2024

<https://thebulletin.org/magazine/2024-03/>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 102(5); 2024 May 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/461078/>

[Reviewed earlier]

**Cell**

Apr 25, 2024 Volume 187 Issue 9 p2029-2342

<https://www.cell.com/cell/current>

***50th Anniversary***

[Reviewed earlier]

**Child Care, Health and Development**

Volume 50, Issue 3 May 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 115, Issue 5 Pages: 907-1175 May 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

**Clinical Therapeutics**

March 2024 Volume 46 Issue 3 p185-304

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 21 Issue 2, April 2024

<https://journals.sagepub.com/toc/ctja/21/2>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 11 May 2024]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 138 March 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 7, Issue 2 / April 2024

<https://www.liebertpub.com/toc/crispr/7/2>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

**Current Medical Research and Opinion**

Volume 40, Issue 3 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

June 2024 - Volume 37 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 11 May 2024]

[No new digest content identified]

**Developing World Bioethics**

Volume 24, Issue 2 Pages: 49-134 June 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 2, 2024

<https://www.tandfonline.com/toc/cdip20/34/2>

[Reviewed earlier]

### **Development Policy Review**

Volume 42, Issue 3 May 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 48, Issue 2 April 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/2>

[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 4 12 April 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 30, Number 4—April 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 46, Issue 2 Pages: 1-35 March–April 2024  
<https://onlinelibrary.wiley.com/toc/25782363/current>

***Indigenous data sovereignty :: Returning clinically relevant results***

[Reviewed earlier]

**Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

**Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

**The European Journal of Public Health**

Volume 34, Issue 2, April 2024

<https://academic.oup.com/eurpub/issue/34/2>

[Reviewed earlier]

**Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

**Foreign Affairs**

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

**Forum for Development Studies**

Volume 51, 2024 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

**Genetics in Medicines**

Volume 26, Issue 5 May 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/5>

*Editorial Open access*

**[Guidance on Use of Race, Ethnicity, and Geographic Origin as Proxies for Genetic Ancestry Groups in Biomedical Publications](#)**

W. Gregory Feero, Robert D. Steiner, Anne Slavotinek, Tiago Faial, ... Kirsten Bibbins-Domingo  
Article 101118

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 11 May 2024]

[No new digest content identified]

### **Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 2 April 29, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 11 May 2024]

[No new digest content identified]

### **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 11 May 2024]

[No new digest content identified]

### **Health and Human Rights**

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

***Special Section: Economic Inequality and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>



[Reviewed earlier]

### **Health Policy and Planning**

Volume 39, Issue 4, May 2024

<https://academic.oup.com/heapol/issue/39/4>

[New issue; No digest content identified]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 11 May 2024]

[No new digest content identified]

### **Human Gene Therapy**

Volume 35, Issue 7-8 / April 2024

<https://www.liebertpub.com/toc/hum/35/7-8>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

### **Immunity**

Mar 12, 2024 Volume 57 Issue 3 p401-612

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 11 May 2024]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 11 May 2024]

[No new digest content identified]

**International Health**

Volume 16, Issue 3, May 2024

<https://academic.oup.com/inthealth/issue/16/3>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

*Table of Contents*

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 11 No. 3 (2024): March 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 53, Issue 2, April 2024

<https://academic.oup.com/ije/issue/53/2>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

*Table of contents*

[Reviewed earlier]

**JAMA**

May 7, 2024, Vol 331, No. 17, Pages 1431-1512

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

**JAMA Health Forum**

April 2024, Vol 5, No. 4

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

**JAMA Pediatrics**

April 2024, Vol 178, No. 4, Pages 326-422

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

**JBIE Evidence Synthesis**

April 2024 - Volume 22 - Issue 4

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

April 2024 Volume 74 Issue 4 p629-860

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

**Journal of Community Health**

Volume 49, Issue 2 April 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-2>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

**Journal of Development Economics**

Volume 168 May 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/168/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 1-2, February–April 2024

<http://journals.sagepub.com/toc/jre/current>

[New issue; No digest content identified]

**Journal of Epidemiology & Community Health**

April 2024 - Volume 78 - 4

<https://jech.bmj.com/content/78/4>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 17, Issue 1 Pages: 1-235 March 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 26, Issue 2 April 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-2>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 229, Issue 3, 15 March 2024

<https://academic.oup.com/jid/issue/229/3>

[Reviewed earlier]

**Journal of International Development**

Volume 36, Issue 3 Pages: 3-1943 April 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

May 2024 - Volume 50 - 5

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 267 April 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/267/suppl/C>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

March/April 2024 - Volume 30 - Issue 2

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

May 2024 Volume 21 Issue 214

<https://royalsocietypublishing.org/toc/rsif/current>

Reviewed earlier]

**Journal of Travel Medicine**

Volume 31, Issue 3 April 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 98 • Number 4 • April 2024

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

## **The Lancet**

May 11, 2024 Volume 403 Number 10439 p1821-1950  
<https://www.thelancet.com/journals/lancet/issue/current>

*Comment*

### **[Measles and rubella vaccine microneedle patch: new hope to reach the unreached children](#)**

Rebecca M Coulborn, Corinne Danet, Alain Alsalhani

*Article*

### **[A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial](#)**

Ikechukwu Adigweme, et al.

Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children...Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children...The safety and immunogenicity data support the accelerated development of the MRV-MNP

## **The Lancet Child & Adolescent Health**

May 2024 Volume 8 Number 5 p311-384  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

## **Lancet Digital Health**

May 2024 Volume 6 Number 5 e299-e373  
<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

## **Lancet Global Health**

May 2024 Volume 12 Number 5 e712-e890  
<https://www.thelancet.com/journals/langlo/issue/current>  
[Reviewed earlier]

## **Lancet Infectious Diseases**

May 2024 Volume 24 Number 5 p437-556, e268-e343  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

## **Lancet Public Health**

May 2024 Volume 9 Number 5 e275-e344  
<https://www.thelancet.com/journals/lanpub/issue/current>  
[Reviewed earlier]

**Lancet Respiratory Medicine**

May 2024 Volume 12 Number 5 p337-418, e31-e35

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 28, Issue 5 May 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-5>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 44 Issue 3, April 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 1 Pages: 1-269 March 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Molecular Therapy**

Apr 03, 2024 Volume 32 Issue 4 p857-1178

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

**Nature**

Volume 629 Issue 8011, 9 May 2024

<https://www.nature.com/nature/volumes/627/issues/8011>

[New issue; No digest content identified]

**Nature Biotechnology**

Volume 42 Issue 4, April 2024

<https://www.nature.com/nbt/volumes/42/issues/4>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 11 May 2024)

[No new digest content identified]

### **Nature Genetics**

Volume 56 Issue 4, April 2024

<https://www.nature.com/ng/volumes/56/issues/4>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 8 Issue 4, April 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/4>

[Reviewed earlier]

### **Nature Medicine**

Volume 30 Issue 4, April 2024

<https://www.nature.com/nm/volumes/30/issues/4>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 23 Issue 4, April 2024

<https://www.nature.com/nrd/volumes/23/issues/4>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 25 Issue 4, April 2024

<https://www.nature.com/nrg/volumes/25/issues/4>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 24 Issue 4, April 2024

<https://www.nature.com/nri/volumes/24/issues/4>

[Reviewed earlier]

### **New England Journal of Medicine**

Volume 390 No. 18 May 9, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

#### **[The Public Good on the Docket — The Supreme Court's Evolving Approach to Public Health](#)**

J.M. Sharfstein and L.O. Gostin

*Abstract*

Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent  $\beta$ -thalassemia mark the dawn of the era of gene editing in medicine. But ensuring access will be challenging.

#### **[Welcoming the Era of Gene Editing in Medicine](#)**

G.Q. Daley

*Abstract*



Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent  $\beta$ -thalassemia mark the dawn of the era of gene editing in medicine. But ensuring access will be challenging.

*Editorial*

### **Extending Gene Medicines to All in Need**

J.M. McCune and H.-P. Kiem

### **NEJM Evidence**

Volume 3 No. 4 April 2024

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/njpvaccines/>

[Accessed 11 May 2024]

[No new digest content identified]

### **Pediatrics**

Volume 153, Issue 5 May 2024

<https://publications.aap.org/pediatrics/issue/153/5>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 42, Issue 4 April 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-4>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 11 May 2024)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 11 May 2024)

[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 11 May 2024)

**[The synergistic impact of Universal Health Coverage and Global Health Security on health service delivery during the Coronavirus Disease-19 pandemic: A difference-in-difference study of childhood immunization coverage from 192 countries](#)**

Sooyoung Kim, Tyler Y. Headley, Yesim Tozan

Research Article | published 10 May 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003205>

*Abstract*

Universal Health Coverage (UHC) and Global Health Security (GHS) are two high-priority global health agendas that seek to foster health system resilience against health emergencies. Many countries have had to prioritize one agenda over the other due to scarce resources and political pressures. To aid policymakers' decision-making, this study investigated the individual and synergistic effects of countries' UHC and GHS capacities in safeguarding essential health service delivery during the COVID-19 pandemic. We used a quasi-experimental difference-in-difference methodology to quantify the relationship between 192 countries' progress towards UHC and GHS and those countries' abilities to provide 12 essential childhood immunization services between 2015 and 2021. We used the 2019 UHC Service Coverage Index (SCI) to divide countries into a "high UHC group" (UHC SCI $\geq$ 75) and the rest (UHC SCI < 75), and similarly used the 2019 GHS Index (GHSI) to divide countries into a "high GHS group" (GHSI $\geq$ 65) and the rest (GHSI < 65). All analyses were adjusted for potential confounders. Countries with high UHC scores prevented a 1.14% (95% CI: 0.39%, 1.90%) reduction in immunization coverage across 2020 and 2021 whereas countries with high GHSI scores prevented a 1.10% (95% CI: 0.57%, 1.63%) reduction in immunization coverage over the same time period. The stratified DiD models showed that across both years, high UHC capacity needed to be augmented with high GHS capacity to prevent a decline in immunization coverage while high GHS alone was able to safeguard immunization coverage. This study found that greater progress towards both UHC and GHS capacities safeguarded essential health service delivery during the pandemic but only progress towards GHS capacity was both a necessary and likely sufficient element for yielding this protective effect. Our results call for strategic investments into both health agendas and future research into possible synergistic effects of the two health agendas.

**PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 11 May 2024)

[No new digest content identified]

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 11 May 2024)

[No new digest content identified]

**PLoS One**

<http://www.plosone.org/>

[Accessed 11 May 2024]

**[COVID-19 and COVID-19 vaccination experiences and perceptions among health workers during the pandemic in Ebonyi state, Nigeria: An analytical cross-sectional study](#)**

Ugwu I. Omale, Cordis O. Ikegwuonu, Glory E. Nkwo, Ugochi I. A. Nwali, Olaedo O. Nnachi, Okechukwu O. Ukpabi, Ifeyinwa M. Okeke, Richard L. Ewah, Osarhiemen Iyare, Chidinma I. Amuzie, Onyinyechukwu U. Oka, Victor U. Uduma, Azuka S. Adeke  
Research Article | published 09 May 2024 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0303172>

**[How did we protect children against COVID-19 in Iran? Prevalence of COVID-19 and vaccination in the socio-economic context of COVID-19 epidemic](#)**

Meroe Vameghi, Mohammad Saatchi, Giti Bahrami, Farin Soleimani, Marzieh Takaffoli  
Research Article | published 09 May 2024 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0303043>

**[COVID-19 vaccine hesitancy among adults in India: A primary study based on health behavior theories and 5C psychological antecedents model](#)**

Sumit Aggarwal, Lucky Singh, Umaer Alam, Saurabh Sharma, Shashi Kala Saroj, Kamran Zaman, Mohd Usman, Rajni Kant, Himanshu Kumar Chaturvedi  
Research Article | published 09 May 2024 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0294480>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 11 May 2024]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

May 7, 2024 vol. 121 no. 19

<https://www.pnas.org/toc/pnas/121/19>

[New issue; No digest content identified]

**PNAS Nexus**

Volume 3, Issue 4, April 2024

<https://academic.oup.com/pnasnexus/issue/3/3>

[Reviewed earlier]

**Prehospital & Disaster Medicine**

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 181 April 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/181/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

May 2024 Volume 291 Issue 2022

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

## **Public Health**

Volume 230 Pages e1-e6, 1-232 (May 2024)

<https://www.sciencedirect.com/journal/public-health/vol/230/suppl/C>

*Research article Open access*

[\*\*Nurses' preferences regarding MenACWY conjugate vaccines attributes: a discrete choice experiment in Spain\*\*](#)

J.A. Forcada-Segarra, I. Cuesta-Esteve, A. García Pérez, R. Sancho Martínez, ... J.L. López-Belmonte  
Pages 163-171

## **Public Health Ethics**

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

## **Public Health Genomics**

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

## **Public Health Reports**

Volume 139 Issue 2, March/April 2024

<https://journals.sagepub.com/toc/phrg/139/2>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 34 Issue 6, May 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

## **Research Ethics**

Volume 20 Issue 2, April 2024

<http://journals.sagepub.com/toc/reab/current>

***Special collection: Research Integrity and Research Misconduct***

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 11 May 2024]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

6 May 2024

**[Digital health in Latin America: current legislation and ethical aspects](#)**

Original research | Spanish |

6 May 2024

**[Prioritization criteria in policies and management of human resources for health: a proposal for a validated methodology](#)**

Original research | English |

**Risk Analysis**

Volume 44, Issue 5 Pages: 1007-1267 May 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 11 May 2024]

[Reviewed earlier]

**Science**

Volume 384| Issue 6696| 10 May 2024

<https://www.science.org/toc/science/current>

*In Depth*

**[Report offers harsh verdict on global polio vaccine switch](#)**

BY Leslie Roberts

09 May 2024: 608-609 FULL ACCESS

Draft evaluation calls 2016 decision to change oral vaccines a “failure”

**Science and Engineering Ethics**

Volume 30, Issue 3 June 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-3>

[New issue; No digest content identified]

**Science Translational Medicine**

Volume 16| Issue 746| 8 May 2024

<https://www.science.org/toc/stm/current>

*Viewpoints*

**[Nothing about us without us: Advocacy and engagement in genetic medicine](#)**

BY Olabimpe Olayiwola, et al.

08 May 2024

*New genetic medicines for sickle cell disease highlight the need for greater community advocacy to ensure access for all.*

**Abstract**

The development of new genetic medicines to treat sickle cell disease highlights the need for greater collaboration between researchers and people with lived experiences. Drawing on the adage "Nothing about us, without us," we call for increased ...

*Reviews*

**[The translational gap for gene therapies in low- and middle-income countries](#)**

BY Kevin W. Doxzen, et al

08 May 2024

*Local capacity should be prioritized for gene therapies that combat diseases prevalent in low- and middle-income countries.*

**Abstract**

Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective ...

**Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 11 May 2024]

[No new digest content identified]

**Social Science & Medicine**

Volume 346 April 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/346/suppl/C>

[Reviewed earlier]

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 11 May 2024]

[No new digest content identified]

**Theoretical Medicine and Bioethics**

Volume 45, Issue 2 April 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

**Travel Medicine and Infectious Diseases**

Volume 58 March–April 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/58/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 29, Issue 5 Pages: i-iv, 343-445 May 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

*REVIEWS* Open Access

### **[The epidemiological profile of incidence and mortality from epidemics in complex humanitarian emergencies from 1990 to 2022 – A scoping review](#)**

Pedro Arcos González, Julián Cabria Fernández, Rick Kye Gan, Ángel Fernández Camporro, José Antonio Cernuda Martínez

Pages: 343-353

First Published: 13 March 2024

## **Vaccine**

Volume 42, Issue 13 Pages 3145-3272 (10 May 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/13>

*Selected Content*

*Editorial No access*

### **[Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic](#)**

Peter J. Pitts, Gregory A. Poland

Pages 3145-3147

*Research article Open access*

### **[Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia](#)**

Ramona Muttucumaru, Colleen L. Lau, Alan Leeb, Deborah J. Mills, ... Luis Furuya-Kanamori

Pages 3166-3171

*Research article Abstract only*

### **[COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants](#)**

Namyeon Lee, Yoorim Hong, Ciera E. Kirkpatrick, Sisi Hu, ... Amanda Hinnant

Pages 3197-3205

*Research article Abstract only*

### **[Prevalence of and factors associated with zero-dose and under-immunized children in selected areas of Bangladesh: Findings from Lot Quality Assurance Sampling Survey](#)**

Hemel Das, Zerín Jannat, Kaniz Fatema, Jannat-E-Tajreen Momo, ... Tasnuva Wahed

Pages 3247-3256

*Research article Abstract only*

### **[Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil](#)**

Eanes Torres Pereira, Sylvia Iasulaitis, Bruno Cardoso Greco

Pages 3263-3271

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 11 May 2024]

*Open Access Article*

**[Determinants of Parental Intention to Vaccinate Young Adolescent Girls against the Human Papillomavirus in Taiwan: An Online Survey Study](#)**

by Pei-Yun Lin, Tai-Ling Liu, Li-Ming Chen, Meng-Jung Liu, Yu-Ping Chang, Ching-Shu Tsai and Cheng-Fang Yen

Vaccines 2024, 12(5), 529; <https://doi.org/10.3390/vaccines12050529> (registering DOI) - 11 May 2024

*Abstract*

Since 2018, Taiwan has included the human papillomavirus (HPV) vaccination into its national immunization program for junior high school girls. However, the reports of side effects following vaccination have increased parental concerns. This study investigated parental intentions regarding the HPV vaccination for their...

**Value in Health**

May 2024 Volume 27 Issue 5 p543-686

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

**World Development**

Volume 177 May 2024

<https://www.sciencedirect.com/journal/world-development/vol/177/suppl/C>

[New issue; No digest content identified]

.....

.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

***Pre-Print Servers***

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 11 May 2024]

*Selected Research*

*No new digest content identified.*

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 11 May 2024]

*[Filter: All articles]*



## **Mapping the distribution and describing the first cases from an ongoing outbreak of a New Strain of mpox in South Kivu, Eastern Democratic Republic of Congo between September 2023 to April 2024**

Leandre Murhula Sr., David F. Nieuwenhuijse, Pacifique Ndishimye, Jean Claude Udahemuka, Bilembo Kitwanda Steeven, Nzigire Barhatwira Gisele, Jean Pierre Musabyimana, Baganda Ntahuma Daniel, Theophile Kiluba wa Kiluba, Franklin Kumbana Mweshi, Polepole Ngabo, Theophile Tambala, Bahati Mutalemba Chance, Leandre Mutimbwa Mambo, Leonard Schuele, Justin Bengehya Mbiribindi, Gustavo Sganzerla Martinez, David J Kelvin, Gaston Lubambo Maboko, Trudie A. Lang, Frank M. Aarestrup, Christian Gortazar, Marion Koopmans, Freddy Belesi Siangoli, Mazambi Mambo Divin  
medRxiv 2024.05.10.24307057; doi: <https://doi.org/10.1101/2024.05.10.24307057>

## **Tetanus vaccination is associated with decreased incidence of Parkinson's disease and slower progression**

Ariel Israel, Eli Magen, Eugene Merzon, Eytan Ruppin, Shlomo Vinker, Nir Giladi  
medRxiv 2024.05.03.24306800; doi: <https://doi.org/10.1101/2024.05.03.24306800>

## **Assessing DxGPT: Diagnosing Rare Diseases with Various Large Language Models**

Juanjo do Olmo, Javier Logrono, Carlos Mascias, Marcelo Martinez, Julian Isla  
medRxiv 2024.05.08.24307062; doi: <https://doi.org/10.1101/2024.05.08.24307062>

### *Abstract*

Diagnosing rare diseases is a significant challenge in healthcare, with patients often experiencing long delays and misdiagnoses. The large number of rare diseases and the difficulty for doctors to be familiar with all of them contribute to this problem. Artificial intelligence, particularly large language models (LLMs), has shown promise in improving the diagnostic process by leveraging their extensive knowledge to help doctors navigate the complexities of diagnosing rare diseases. Foundation 29 presents a comprehensive evaluation of DxGPT, a web-based platform designed to assist healthcare professionals in the diagnostic process for rare diseases. The platform currently utilizes GPT-4, but this study also compares its performance with other large language models, including Claude 3, Gemini 1.5 Pro, Llama, Mistral, Mixtral, and Cohere Command R+. It is crucial to emphasize that DxGPT is not a medical device but rather a decision support tool that aims to aid in clinical reasoning. This study extends beyond initial synthetic patient cases, incorporating real-world data from the RAMEDIS and Peking Union Medical College Hospital (PUMCH) datasets. The analysis followed two main metrics: Strict Accuracy (P1), how often the first diagnostic suggestion agreed with the real diagnosis, and Top-5 Accuracy (P1 + P5), how often the right diagnosis was in the top five suggestions. The results show a complex picture of diagnostic accuracy, with performance varying significantly across models and datasets: - On the synthetic dataset, closed models like GPT-4, Claude, and Gemini exhibited relatively high accuracy. Open models like Llama 3 and Mixtral performed reasonably well, though lagging behind. - On the RAMEDIS rare disease cases, Claude 3 Opus model demonstrated 55% Strict Accuracy and 70% Top-5 Accuracy, outperforming other closed models. Open models like Llama 3 and Mixtral showed moderate accuracy. - The PUMCH dataset proved challenging for all models, with the highest Strict Accuracy at 59.46% (GPT-4 Turbo 1106) and Top-5 Accuracy at 64.86%. These findings demonstrate the potential of DxGPT and LLMs in improving diagnostic methods for rare diseases. However, they also emphasize the need for further validation, particularly in real-world clinical settings, and comparison with human expert diagnoses. Successful integration of AI into medical diagnostics will require collaboration between researchers, clinicians, and regulatory bodies to ensure safety, efficacy, and ethical deployment.

## **The Peruvian Genome Project: expanding the global pool of genome diversity from South America**

Heinner Guio, Omar Caceres, Cesar Sanchez, Carlos Padilla, Omar Trujillo, Victor Borda, Luis Jaramillo-Valverde, Julio A. Poterico, Carolina Silva-Carvalho, Mary Horton, Cristina M Lanata, Alessandra Carnevale, Sandra Romero-Hidalgo, Samuel Canizales-Quinteros, Víctor Acuña-Alonzo, Pedro Novoa-Bellota, Roberto Frisancho, Ruth Shady-Solis, Pedro Flores-Villanueva, Timothy D. O'Connor, Manuel Corpas, Eduardo Tarazona-Santos

medRxiv 2024.05.05.24306840; doi: <https://doi.org/10.1101/2024.05.05.24306840>

#### *SUMMARY*

The process of inhabiting the Americas by ancestral native American populations involved many individuals settling in the Peruvian Andes and Amazonian regions. Due to Latin American countries representing less than 1% of the human genome data available in public reference databases, the evolution and migration processes involved in adapting to this unique geography have not yet been fully explained. The Peruvian Genome Project is an initiative first of its kind, started in 2011, to address the underrepresentation of genomic data from native South American populations. This project has collected to date 1,149 samples from 17 traditional native and 13 mestizo (mixed of native, African, and European ancestry) communities. Currently, 150 whole genomes and 873 array-genotyped individuals have been sequenced from across the geography of Western South America, including coastal, Andes, and Amazonian regions. We discovered 1.6 million novel genetic variants with varying frequencies, indicative of local environmental adaptations and population drift. These novel variants allow us to infer local evolutionary traits and population-specific allele frequencies for people living at different altitudes, as well as varying adaptations to pathogens and living conditions. The Peruvian Genome Project is the result of more than a decade of work in sample selection, logistics, and approved regulatory community engagement, designed to enhance the human genome pool of diversity of native Americans. The data collected here enable the targeted characterization of endemic diseases, trait adaptations, and new variants of clinical significance in South America. The Peruvian Genome Project represents a step forward in international and multidisciplinary efforts to make precision medicine more inclusive and accessible for underrepresented communities in Latin America, offering significant potential for drug development and diagnostics in a neglected continent.

#### **Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical Trial**

Gonzalo Perez-Marc, Lorena M. Coria, Ana Ceballos, Juan Manuel Rodriguez, Mónica E. Lombardo, Laura Bruno, Federico Páez Córdoba, Clara G. Fascetto Cassero, Melina Salvatori, Mayra Rios Medrano, Fabiana Fulgenzi, María F. Alzogaray, Analía Mykietiuik, Ignacio Leandro Uriarte, Nicolás Itcovici, Tomás Smith Casabella, Gonzalo Corral, Miriam Bruno, Oscar Roldán, Sebastián A. Nuñez, Florencia Cahn, Gustavo A. Yerino, Alejandra Bianchi, Virginia Micaela Braem, Analía Christmann, Santiago Corradetti, Martín Claudio Darraidou, Lucila Di Nunzio, Tatiana Belén Estrada, Rocío López Castelo, Carla Graciela Marchionatti, Lucila Pitocco, Virginia Macarena Trias Uriarte, Cristian Jorge Wood, Romina Zadoff, Florencia Bues, Rosa M. Garrido, Laboratorio Pablo Cassará group for ARVAC, Agostina Demaría, Lineia Prado, Celeste Pueblas Castro, Lucas Saposnik, Jorge Geffner, Federico Montes de Oca, Julio C. Vega, Juan Fló, Pablo Bonvehí, Jorge Cassará, Karina A. Pasquevich, Juliana Cassataro

medRxiv 2024.05.06.24306575; doi: <https://doi.org/10.1101/2024.05.06.24306575>

#### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-No new digest content identified.]*

## Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 11 May 2024]

*Selected Research*

*Research Article Open Access*

### [Investigating the feasibility and potential of combining industry AMR monitoring systems: a comparison with WHO GLASS](#)

[version 1; peer review: awaiting peer review]

Eve Rahbé \*, Aleksandra Kovacevic \*, Lulla Opatowski, Quentin J. Leclerc

*Background*

Efforts to estimate the global burden of antimicrobial resistance (AMR) have highlighted gaps in existing surveillance systems. Data gathered from hospital networks globally by pharmaceutical industries to monitor antibiotic efficacy in different bacteria represent an additional source to track the temporal evolution of AMR. Here, we analysed available industry monitoring systems to assess to which extent combining them could help fill the gaps in our current understanding of AMR levels and trends.

\* \* \* \*

## ***Think Tanks***

**Brookings** [to 11 May 2024]

<http://www.brookings.edu/>

*Research*

*No new digest content identified.*

**Center for Global Development** [to 11 May 2024]

<https://www.cgdev.org/>

*All Research [Selected]*

*No new digest content identified.*

**Chatham House** [to 11 May 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 11 May 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 11 May 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 11 May 2024]  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*  
*No new digest content identified.*

**McKinsey Global Institute** [to 11 May 2024]  
<https://www.mckinsey.com/mgi/overview>  
*Latest Research*  
*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 11 May 2024]  
<https://odi.org/en/publications/>  
*Publications [Selected]*  
*No new digest content identified.*

**Pew Research Center** [to 11 May 2024]  
<https://www.pewresearch.org/>  
*Latest Publications [Selected]*  
*No new digest content identified.*

**Rand** [to 11 May 2024]  
<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*No new digest content identified.*

**Urban Institute** [to 11 May 2024]  
<https://www.urban.org/publications>  
[New Research Publications - Selected](#)

**World Economic Forum** [to 11 May 2024]  
<https://agenda.weforum.org/press/>  
*Media [Selected]*  
*No new digest content identified.*

.....  
.....

### **Public Consultations/Call for Inputs/Call for Papers**

*No new digest content identified.*

\* \* \* \*

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*  
\* \* \* \*